Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. But until now, no one had directly compared their performance in people without ...

The study will look at whether the drug, marketed as Mounjaro and Zepbound, will reduce the number of people leaving the ...

By contrast, 1-year discontinuation rates in the main phase 3 randomized clinical trials were 17.1% with once-weekly semaglutide 2.4 mg , and 14.2%-16.4% for tirzepatide , the authors noted.

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

In clinical practice, injectable glucagon-like peptide-1 (GLP-1) receptor agonists for obesity treatment appear less effective than in clinical trials, largely due to early discontinuation and low ...

Tirzepatide dose escalation is slower in real-world settings than clinical trials among individuals without type 2 diabetes (T2D) but with multiple comorbidities, according to study results ...

Those who did not discontinue treatment and were on higher maintenance doses of the medications lost 13.7% of their body weight with semaglutide and 18.0% with tirzepatide, close to the average ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised by the drugs' clinical trials, a new study says.

Encouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis support further investigation into the GIP–GLP-1 receptor agonist for liver disease.

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...

In real-world cohort, percentage weight reduction at 1 year was 3.6%, 6.8%, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.